Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: Binding studies and crystal structure

Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida 32224, USA.
Journal of Biological Chemistry (Impact Factor: 4.57). 03/2012; 287(19):15935-46. DOI: 10.1074/jbc.M112.341156
Source: PubMed


Matrix metalloproteinase 10 (MMP-10, stromelysin-2) is a secreted metalloproteinase with functions in skeletal development,
wound healing, and vascular remodeling; its overexpression is also implicated in lung tumorigenesis and tumor progression.
To understand the regulation of MMP-10 by tissue inhibitors of metalloproteinases (TIMPs), we have assessed equilibrium inhibition
constants (Ki) of putative physiological inhibitors TIMP-1 and TIMP-2 for the active catalytic domain of human MMP-10 (MMP-10cd) using
multiple kinetic approaches. We find that TIMP-1 inhibits the MMP-10cd with a Ki of 1.1 × 10−9 m; this interaction is 10-fold weaker than the inhibition of the similar MMP-3 (stromelysin-1) catalytic domain (MMP-3cd) by
TIMP-1. TIMP-2 inhibits the MMP-10cd with a Ki of 5.8 × 10−9 m, which is again 10-fold weaker than the inhibition of MMP-3cd by this inhibitor (Ki = 5.5 × 10−10 m). We solved the x-ray crystal structure of TIMP-1 bound to the MMP-10cd at 1.9 Å resolution; the structure was solved by
molecular replacement and refined with an R-factor of 0.215 (Rfree = 0.266). Comparing our structure of MMP-10cd·TIMP-1 with the previously solved structure of MMP-3cd·TIMP-1 (Protein Data
Bank entry 1UEA), we see substantial differences at the binding interface that provide insight into the differential binding of stromelysin
family members to TIMP-1. This structural information may ultimately assist in the design of more selective TIMP-based inhibitors
tailored for specificity toward individual members of the stromelysin family, with potential therapeutic applications.

Download full-text


Available from: Evette S Radisky
  • Source
    • "Of particular interest were the genes encoding matrix metalloproteinase 10 (MMP10), also referred to as stromelysin 2, which was upregulated by 3.3-fold, and its inhibitor tissue inhibitor of metalloproteinase 2 (TIMP2), which was downregulated by 3.2-fold. MMP10 is a secreted proteinase that degrades the extracellular matrix, and TIMP2 inhibits MMP10 activity [22]. Thus, the upregulation of MMP10 and concomitant downregulation of TIMP2 would be predicted to disrupt cell-cell adhesion and promote invasion and metastasis of YY1 knockdown BXPC-3 cells. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Increasing evidence indicates an important role of transcription factor Yin Yang-1 (YY1) in human tumorigenesis. However, its function in cancer remains controversial and the relevance of YY1 to pancreatic ductal adenocarcinoma (PDAC) remains to be clarified. In this study, we detected YY1 expression in clinical PDAC tissue samples and cell lines using quantitative RT-PCR, immunohistochemistry and western blotting. We also detected MUC4 and MMP10 mRNA levels in 108 PDAC samples using qRT-PCR and analyzed the correlations between YY1 and MUC4 or MMP10 expression. The role of YY1 in the proliferation, invasion and metastatic abilities of PDAC cells in vitro was studied by CCK-8 assay, cell migration and invasion assays. In vivo pancreatic tumor growth and metastasis was studied by a xenogenous subcutaneously implant model and a tail vein metastasis model. The potential mechanisms underlying YY1 mediated tumor progression in PDAC were explored by digital gene expression (DGE) sequencing, signal transduction pathways blockage experiments and luciferase assays. Statistical analysis was performed using the SPSS 15.0 software. We found that the expression of YY1 in PDACs was higher compared with their adjacent non-tumorous tissues and normal pancreas tissues. However, PDAC patients with high level overexpression of YY1 had better outcome than those with low level overexpression. YY1 expression levels were statistically negatively correlated with MMP10 expression levels, but not correlated with MUC4 expression levels. YY1 overexpression suppressed, whereas YY1 knockdown enhanced, the proliferation, invasion and metastatic properties of BXPC-3 cells, both in vitro and in vivo. YY1 suppresses invasion and metastasis of pancreatic cancer cells by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism. The present study suggested that YY1 plays a negative role, i.e. is a tumor suppressor, in PDAC, and may become a valuable diagnostic and prognostic marker of PDAC.
    Full-text · Article · May 2014 · Molecular Cancer
  • Source
    • "Mature secreted full-length rhTIMP-1 was expressed using the pTT/TIMP-1 construct transfected into HEK 293E cells [30], and was purified by SP-Sepharose chromatography as we have described previously [31]. Four mutant pTT/TIMP-1 constructs were generated to introduce a free Cys residue (R180C, S181C, Q182C, and A184C) using the Stratagene QuikChange mutagenesis kit (Agilent Technologies, Wilmington, DE, USA) according to the manufacturer’s protocols. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Excess proteolytic activity of matrix metalloproteinases (MMPs) contributes to the development of arthritis, cardiovascular diseases and cancer progression, implicating these enzymes as therapeutic targets. While many small molecule inhibitors of MMPs have been developed, clinical uses have been limited, in part by toxicity and off-target effects. Development of the endogenous tissue inhibitors of metalloproteinases (TIMPs) as recombinant biopharmaceuticals represents an alternative therapeutic approach; however, the short plasma half-life of recombinant TIMPs has restricted their potential in this arena. To overcome this limitation, we have modified recombinant human TIMP-1 (rhTIMP-1) by PEGylation on lysine residues. We analyzed a mixture of mono-and di-PEGylated rhTIMP-1 species modified by attachment of 20 kDa mPEG chains (PEG 20K -TIMP-1), as confirmed by SELDI-TOF mass spectrometry. This preparation retained complete inhibitory activity toward the MMP-3 catalytic domain and partial inhibitory activity toward full length MMP-9. Pharmacokinetic evaluation showed that PEGylation extended the plasma half-life of rhTIMP-1 in mice from 1.1 h to 28 h. In biological assays, PEG 20K -TIMP-1 inhibited both MMP-dependent cancer cell invasion and tumor cell associated gelatinase activity. Overall these results suggest that PEGylated TIMP-1 exhibits improved potential for development as an anti-cancer recombinant protein therapeutic, and additionally may offer potential for clinical applications in the treatment of other diseases.
    Full-text · Article · Nov 2012 · PLoS ONE
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Matrix metalloproteinases (Mmps) stimulate tumor invasion and metastasis by degrading the extracellular matrix. Here we reveal an unexpected role for Mmp10 (stromelysin 2) in the maintenance and tumorigenicity of mouse lung cancer stem-like cells (CSC). Mmp10 is highly expressed in oncosphere cultures enriched in CSCs and RNAi-mediated knockdown of Mmp10 leads to a loss of stem cell marker gene expression and inhibition of oncosphere growth, clonal expansion, and transformed growth in vitro. Interestingly, clonal expansion of Mmp10 deficient oncospheres can be restored by addition of exogenous Mmp10 protein to the culture medium, demonstrating a direct role for Mmp10 in the proliferation of these cells. Oncospheres exhibit enhanced tumor-initiating and metastatic activity when injected orthotopically into syngeneic mice, whereas Mmp10-deficient cultures show a severe defect in tumor initiation. Conversely, oncospheres implanted into syngeneic non-transgenic or Mmp10(-/-) mice show no significant difference in tumor initiation, growth or metastasis, demonstrating the importance of Mmp10 produced by cancer cells rather than the tumor microenvironment in lung tumor initiation and maintenance. Analysis of gene expression data from human cancers reveals a strong positive correlation between tumor Mmp10 expression and metastatic behavior in many human tumor types. Thus, Mmp10 is required for maintenance of a highly tumorigenic, cancer-initiating, metastatic stem-like cell population in lung cancer. Our data demonstrate for the first time that Mmp10 is a critical lung cancer stem cell gene and novel therapeutic target for lung cancer stem cells.
    Full-text · Article · Jun 2012 · PLoS ONE
Show more